Deborah Mukherji· @dmukherji · X·· 2 天前评分70
正文 · 机器翻译
生活质量在 mCRPC 中至关重要
在 #ESMO26 上，PR21 显示 Lu-PSMA-617 与多西他赛相比，患者报告的生活质量更好，且 rPFS 无显著差异。
选择治疗序列时的一个重要考量 #DKhalaf @OncoAlert
256 浏览 · 8 赞 · 6 转发 · 0 回复
会议摘要
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgLBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgNCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上
- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：Deborah Mukherji · x.com